JULIA ARGYROU Endometriosis Centre



# Clinical factors that increase the risk for

## endometriosis recurrence

Sarah Holdsworth-Carson<sup>1,2,3</sup>, Jessica Chung<sup>2,3,4</sup> Dorothy Machalek<sup>3,5</sup>, Meaghan Griffiths<sup>2,3</sup>, Byung Kyu Jun<sup>2,3</sup>, Rebecca Li<sup>2,3</sup>, Jacqueline Donoghue<sup>2,3</sup>, Grant Montgomery<sup>6</sup>, Uri Dior<sup>7</sup>, Charlotte Reddington<sup>2,3</sup>, Jane Girling<sup>2,3,8</sup>, Martin Healey<sup>2,3</sup> and Peter Rogers<sup>2,3</sup>.

<sup>1</sup> Julia Argyrou Endometriosis Centre, Epworth HealthCare, Richmond VIC, Australia, <sup>2</sup> Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Australia, <sup>3</sup> Gynaecology Research Centre, Royal Women's Hospital, Parkville, Melbourne, Australia, <sup>4</sup> Melbourne Bioinformatics, University of Melbourne, Parkville VIC, Melbourne, Australia, <sup>5</sup> Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia, <sup>6</sup> The Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia, <sup>7</sup> Endometriosis Treatment Centre of the Gynaecology Department, Hadassah University Hospital, Jerusalem, Israel, <sup>8</sup> Department of Anatomy, University of Otago, Dunedin, New Zealand.

### Introduction:

Despite surgical treatment endometriosis can reoccur in up to 67% of patients. Diagnosing disease recurrence is challenging, as symptoms can present in the absence of lesions. Therefore, the decision to re-operate for suspected recurrent endometriosis is not a simple one.

### **Results:**

Several variables were associated with increased probability of recurrence (univariate analysis; hazard ratio adjusted p-values and Kaplan Meier pvalues <0.05) (Table 1):

#### Table 1: Probability of disease recurrence


		Univariate survival analysis					Multivariate
Factor	n	HR (95% CI)	Adj. P-value	Probability of no disease recurrence		Kaplan Meier	Lassa Coof
				at 2 years	at 5 years	P-value	Lasso Coef.
Age (35+ years)	82	3.14 (1.44 - 6.87)	0.019	0.83 (0.75 - 0.93)	0.64 (0.51 - 0.79)	0.010	0.000
Gravidity (3+)	14	3.55 (1.49 - 8.46)	0.019	0.73 (0.51 - 1.00)	0.46 (0.24 - 0.87)	0.010	0.000
Parity (1-2)	43	2.75 (1.49 - 5.06)	0.007	0.78 (0.66 - 0.93)	0.57 (0.42 - 0.78)	0.001	0.000
Obese BMI (kg/m <sup>2</sup> )	48	2.42 (1.25 - 4.70)	0.035	0.88 (0.78 - 0.99)	0.63 (0.48 - 0.83)	0.032	0.000
Self-reported uterine fibroids	20	3.50 (1.65 - 7.41)	0.007	0.73 (0.56 - 0.96)	0.57 (0.36 - 0.89)	< 0.001	0.000
Self-reported adenomyosis	22	3.63 (1.78 - 7.42)	0.003	0.60 (0.42 - 0.86)	0.54 (0.36 - 0.82)	<0.001	0.621
Uterine volume on U/S (ml) (Log)	343	9.51 (2.14 - 42.34)	0.016	-	-		N/A
Adenomyosis (U/S heterogeneous myometrium)	10	3.43 (1.31 - 8.98)	0.040	0.80 (0.59 - 1.00)	N/A	0.008	N/A
Endometriosis present on U/S (excluding OMA)	15	5.97 (2.96 - 12.07)	< 0.001	0.51 (0.30 - 0.86)	0.23 (0.07 - 0.69)	< 0.001	N/A
Adhesions present on U/S	17	3.69 (1.84 - 7.40)	0.002	0.59 (0.40 - 0.88)	0.39 (0.21 - 0.73)	< 0.001	N/A
Self-reported previous diagnosis of endometriosis	35	31.30 (17.68 - 55.40)	< 0.001	0.40 (0.27 - 0.60)	0.03 (0.00 - 0.20)	< 0.001	2.943
Stage 1 (rASRM)	195	-		0.96 (0.93 - 0.99)	0.89 (0.84 - 0.94)	< 0.001	-
Stage 2 (rASRM)	55	3.22 (1.51 - 6.89)	0.014	0.87 (0.78 - 0.97)	0.67 (0.53 - 0.86)		0.000
Stage 3 (rASRM)	38	3.03 (1.28 - 7.15)	0.040	0.91 (0.83 - 1.00)	0.61 (0.41 - 0.90)		0.000
Stage 4 (rASRM)	55	5.96 (3.07 - 11.57)	<0.001	0.75 (0.64 - 0.88)	0.57 (0.44 - 0.74)		0.000
Adhesions	140	5.26 (2.83 - 9.79)	< 0.001	0.83 (0.77 - 0.90)	0.59 (0.50 - 0.70)	< 0.001	0.000
Deep ovarian lesion(s)	85	2.00 (1.17 - 3.42)	0.040	0.87 (0.80 - 0.95)	0.65 (0.53 - 0.80)	0.010	0.000
Deep peritoneal lesion(s)	108	2.72 (1.61 - 4.59)	0.002	0.79 (0.71 - 0.87)	0.68 (0.59 - 0.79)	< 0.001	0.000
Bowel lesion(s)	57	5.52 (3.25 - 9.36)	<0.001	0.65 (0.53 - 0.80)	0.46 (0.32 - 0.65)	< 0.001	0.346

### Aim:

To examine clinical information from surgically confirmed recurrent endometriosis cases to identify clinical factors that were associated with an increased risk of recurrent disease.

### Materials & Methods:

Participants from the Melbourne Endometriosis Research Cohort (Royal Women's Hospital) with ≥2 surgically confirmed endometriosis diagnoses were included in the analysis (n=343). Medical The multivariate analysis identified which risk factors provided a good model for prediction of disease recurrence (non-zero Lasso coefficients, Table 1 and Figure 1).



**Figure 1:** Survival analysis on data from patients with confirmed endometriosis. A) self-reported previous diagnosis of endometriosis, B) self-reported adenomyosis, C) presence of adhesions (surgically recorded), and D) presence of lesions on the bowel (surgically recorded). Dashed vertical lines indicate 2 and 5 years following first diagnosis (time 0). Red = no, blue = yes.

(surgical/pathology reports) and questionnaire (patients/surgeons) data were collected. Employing date of surgery, a survival analysis was undertaken and univariate and multivariate co-efficients were calculated.

### **Conclusion & Impact:**

Routine clinical and surgical data collected from patients with confirmed disease recurrence identified several features that were associated with increased probability of recurrence. Those who self-report a previous diagnosis of endometriosis, self-report adenomyosis and had bowel disease (surgically visualised) are at increased risk of recurrence.

#### epworth.org.au



